Placeholder Banner

BIO Expresses Strong Support for TRID Improvement Act

February 12, 2018

Washington, D.C. (February 12, 2018)— The Biotechnology Innovation Organization (BIO) announced its strong support today for H.R. 3978, the TRID Improvement Act. The bill includes a provision known as the Fostering Innovation Act, which offers much needed regulatory relief to small biotechnology firms. 

The Fostering Innovation Act was introduced last year by Reps. Kyrsten Sinema (D-AZ) and Trey Hollingsworth (R-IN) to build on the success of the Jumpstart Our Business Startups (JOBS) Act.  The Fostering Innovation Act extends one vital JOBS Act provision – the temporary exemption from Section 404(b) of Sarbanes-Oxley (SOX) – for an additional five years for pre-revenue small businesses.

“The JOBS Act has stimulated more than 250 biotech IPOs since its enactment in 2012.  These emerging innovators, conducting life-saving research, will directly benefit from the Fostering Innovation Act,” said BIO President and CEO Jim Greenwood. “Under current law, the JOBS Act’s SOX 404(b) exemption expires after five years, but most biotech companies remain pre-revenue for more than a decade.  The Fostering Innovation Act’s extension, which is narrowly targeted to provide relief for the smallest pre-revenue innovators, will allow companies to focus on advancing their research rather than complying with a costly regulatory burden that does not provide significant insights to investors.

“BIO commends Reps. Sinema and Hollingsworth for their leadership on this important issue, and we strongly support passage of the bill.”

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.


Discover More
Washington, DC (November 20, 2020) – Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the Trump administration moved forward with its threat to impose…
"What a historic election for our country! For the first time in 120 years, American voter participation shattered many turnout records.    "At BIO we undertook an effort to mobilize and activate voters in our industry with Biotech Votes…
The Biotechnology Innovation Organization (BIO) today announced a new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds. Announcing the new vision, mission and…